The advent of biologic disease-modifying antirheumatic drugs (bDMARDs) has vastly improved the lives of people with rheumatoid arthritis. In the UK, the NHS picks up the costs of these expensive drugs for people who need them, but elsewhere in the world patients must foot the bill themselves. Reducing the expense, through cost-effective alternatives that can now be developed (biosimilars) is of great interest, so long as they work as well and are as safe.